| Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2016: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2015: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2014: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Outline of Final Research Achievements |
Establishment of new chemotherapy is required for the treatment of hepatocellular carcinoma (HCC) to improve the bad prognosis of patients with unresectable cancer and the frequent recurrence after surgery. In the present study, the effect of c-Met inhibitor on the growth and the invasion of HCC cells was investigated. SU11274, a c-Met inhibitor, was suppressed the proliferation and the invasion of HCC cells in vitro. In addition, the HCC cells treated with SU11274 enhanced its adhesiveness via the up-regulation of e-cadherin. These results suggest that c-Met is a good target for the development of new chemotherapeutic agent.
|
